- Nafamostat mesylate
-
- $0.00 / 1g
-
2026-03-09
- CAS:82956-11-4
- Min. Order: 1g
- Purity: 98.5～101.5%
- Supply Ability: 10kg/month
- Nafamostat mesylate
-
- $5.00/ KG
-
2026-03-09
- CAS:82956-11-4
- Min. Order: 0.10000000149011612KG
- Purity: 99% hplc
- Supply Ability: 5000kg
- Nafamostat mesylate
-
- $37.00 / 10mg
-
2026-03-05
- CAS:82956-11-4
- Min. Order:
- Purity: 99.70%
- Supply Ability: 10g
|
| Product Name: | Nafamostat mesylate | | Synonyms: | 4-((aminoiminomethyl)amino)-benzoicaci6-(aminoiminomethyl)-2-naphthalenyl;6-carbaMiMidoylnaphthalen-2-yl 4-guanidinobenzoate diMethanesulfonate;[amino-[6-[[4-(diaminomethyleneazaniumyl)phenyl]-oxomethoxy]-2-naphthyl]methylene]ammonium;[amino-[6-[4-(diaminomethyleneazaniumyl)benzoyl]oxy-2-naphthyl]methylene]ammonium;[amino-[6-[4-(diaminomethylideneazaniumyl)benzoyl]oxynaphthalen-2-yl]methylidene]azanium;[amino-[6-[4-(diaminomethylideneazaniumyl)phenyl]carbonyloxynaphthalen-2-yl]methylidene]azanium;Nafamostat mesylate, >=98%;5-methyl-1-{6-[(7-oxo-7h-furo[3,2-g]chromen-9-yl)oxy]hexyl}pyrimidine-2,4(1h,3h)-dione | | CAS: | 82956-11-4 | | MF: | C21H25N5O8S2 | | MW: | 539.58 | | EINECS: | 692-168-2 | | Product Categories: | Inhibitors;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;APIs;ProteaseInhibitors;Inhibitor;API;Futhan, FUT-175;82956-11-4;Coronavirus | | Mol File: | 82956-11-4.mol |  |
| | Nafamostat mesylate Chemical Properties |
| Melting point | 259-261°C | | storage temp. | Sealed in dry,Room Temperature | | solubility | Soluble in Water (up to 25 mg/ml). | | form | powder | | color | white to beige | | Merck | 14,6350 | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at 4°C for up to 1 month, or at -80°C for up to 6 months. | | InChI | 1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4) | | InChIKey | SRXKIZXIRHMPFW-UHFFFAOYSA-N | | SMILES | CS(O)(=O)=O.CS(O)(=O)=O.C(OC1=CC=C2C(=C1)C=CC(C(=N)N)=C2)(=O)C1=CC=C(NC(N)=N)C=C1 | | CAS DataBase Reference | 82956-11-4(CAS DataBase Reference) |
| RIDADR | 3077 | | WGK Germany | nwg | | RTECS | DG2736000 | | HS Code | 29252900 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Repr. 2 |
| | Nafamostat mesylate Usage And Synthesis |
| Description | Nafamostat mesylate is a protease inhibitor useful in the treatment of acute pancreatitis. It has anticomplement,
anticoagulant, antikallikrein and other activities, and thus may have additional
utility in the treatment of autoimmune diseases and disseminated intravascular coagulation. | | Chemical Properties | Tan to pale orange solid | | Originator | Torii (Japan) | | Uses | A non-peptide proteaseinhibitor. | | Uses | Nafamostat is an anticoagulant. Broad spectrum serine protease inhibitor. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma | | Brand name | FUTHAN | | Biological Activity | Broad spectrum serine protease inhibitor. Displays selectivity for human tryptase when used at relatively low concentrations. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma. | | Biochem/physiol Actions | Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor. | | Synthesis | By p-guanidinobenzoic acid hydrochloride, 6-amidino groups-beta naphthal, 4,5-dicyano imidazole, methylene dichloride mix, 0-5 ℃ is stirred 1 hour, then improve temperature to 18-22 ℃, insulation reaction 8-12h, filters washed with dichloromethane, gained solid is 2 with methylsulfonic acid adjust pH, obtains nafamostat mesylate. | | storage | Store at +4°C | | Background | Nafamostat Mesylate, also known as FUT-175, is a potent and reversible, broad-spectrum serine protease inhibitor of trypsin, tryptase, and other additional proteases. This small compound has been identified as a key player in the disruption of the inflammatory response via inhibition of the complement system and coagulation cascade. Its wide range of inhibitory activity displays anti-cancer and anti-viral properties and has shown effective inhibition of MERS-CoV by preventing membrane fusion, making it a promising therapeutic candidate against the 2019-nCoV infection. | | References | [1] XINXIN HAN. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity[J]. Chemico-Biological Interactions, 2019, 297: Pages 80-84. DOI:10.1016/j.cbi.2018.10.023 |
| | Nafamostat mesylate Preparation Products And Raw materials |
|